Published in Clin Transl Gastroenterol on December 10, 2015
Enhancing High Value Care in Gastroenterology Practice. Clin Gastroenterol Hepatol (2016) 0.77
Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma. Br J Cancer (2016) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med (2009) 12.16
How should meta-regression analyses be undertaken and interpreted? Stat Med (2002) 8.96
Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol (2008) 7.94
Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med (2002) 6.53
Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology (2013) 4.43
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology (1989) 4.23
Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ (2000) 4.21
Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol (2002) 3.94
Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2009) 3.66
Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med (2003) 3.30
Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology (2002) 3.28
Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 3.06
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol (2000) 2.99
Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut (1998) 2.38
The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.34
Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol (2003) 2.34
Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut (1991) 2.29
Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg (1994) 2.25
Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med (2000) 2.05
Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg (2003) 2.03
Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med (1991) 2.01
Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg (1996) 1.99
Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut (1992) 1.96
Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg (1988) 1.91
Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol (1997) 1.81
Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study. Gut (2014) 1.65
Barrett's esophagus: a retrospective analysis of 13 years surveillance. J Gastroenterol Hepatol (2008) 1.63
Cost effectiveness of detecting Barrett's cancer. Gut (1996) 1.63
Meta-analysis. A quantitative approach to research integration. JAMA (1988) 1.58
Meta analysis: Cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther (2007) 1.50
Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg (2005) 1.40
The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol (1998) 1.35
Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol (2005) 1.23
Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol (2004) 1.17
DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry (1998) 1.13
Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol (2014) 1.13
Screening for Barrett's Esophagus. Gastroenterology (2015) 1.11
Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol (1998) 1.07
Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci (1989) 1.06
Long-term outcome of esophagectomy for high-grade dysplasia or cancer found during surveillance for Barrett's esophagus. J Gastrointest Surg (2006) 1.05
Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br J Surg (2004) 1.01
Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus. Scand J Gastroenterol (2000) 1.01
Barrett's esophagus: incidence and prevalence estimates in a rural Mid-Western population. Am J Gastroenterol (2007) 0.98
Effectiveness and patient satisfaction with nurse-directed treatment of Barrett's esophagus. Am J Gastroenterol (1998) 0.97
Barrett's esophagus. J Gastroenterol Hepatol (2011) 0.97
Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci (2001) 0.95
Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival. Eur J Gastroenterol Hepatol (2005) 0.94
Barrett's oesophagus: results from a 13-year surveillance programme. Eur J Gastroenterol Hepatol (2000) 0.91
Audit of a Barrett's epithelium surveillance database. Eur J Gastroenterol Hepatol (2004) 0.91
Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. Dis Esophagus (2009) 0.90
Surveillance in Barrett's esophagus: an audit of practice. Dig Dis Sci (2009) 0.88
Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. Gruppo Operativo per lo Studio delle Precancerosi Esofagee (GOSPE). Eur J Gastroenterol Hepatol (1997) 0.87
Long-term survival and cost analysis of an annual Barrett's surveillance programme. Eur J Gastroenterol Hepatol (2010) 0.86
Guidelines of the French Society of Digestive Endoscopy: monitoring of Barrett's esophagus. The Council of the French Society of Digestive Endoscopy. Endoscopy (2000) 0.86
Dysplasia detection rate of confirmatory EGD in nondysplastic Barrett's esophagus. Dis Esophagus (2012) 0.84
Esophageal cancer in Canada: trends according to morphology and anatomical location. Can J Gastroenterol (2012) 0.84
Frequency of Barrett's neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study. Endoscopy (2006) 0.83
Surveillance of Barrett's columnar-lined oesophagus in the UK: endoscopic intervals and frequency of detection of dysplasia. Eur J Gastroenterol Hepatol (2009) 0.82
Barrett's oesophagus: an audit of surveillance over a 17-year period. Eur J Gastroenterol Hepatol (2006) 0.82
Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland. Eur J Gastroenterol Hepatol (2005) 0.82
Outcome of endoscopy surveillance for Barrett's oesophagus. ANZ J Surg (2009) 0.80
Low incidence of adenocarcinoma and high-grade intraepithelial neoplasia in patients with Barrett's esophagus: a prospective cohort study. Endoscopy (2008) 0.80
Barrett's esophagus: Macroscopic markers and the prediction of dysplasia and adenocarcinoma. J Gastroenterol Hepatol (2003) 0.80
Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study. Gut (2015) 0.78
Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database. Dis Esophagus (2008) 0.77
A surveillance programme for Barrett's oesophagus in a UK general hospital. Eur J Gastroenterol Hepatol (2007) 0.76
Cross-organism analysis using InterMine. Genesis (2015) 0.88
Creating databases for biological information: an introduction. Curr Protoc Bioinformatics (2013) 0.84
The effect of HIV-hepatitis C co-infection on bone mineral density and fracture: a meta-analysis. PLoS One (2014) 0.78
Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. PLoS One (2017) 0.75
Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. Cancer Med (2017) 0.75